Taking Action in IBD: Modern Strategies and Novel Targets to Improve Patient Outcomes

Activity Details
  • Credit Amounts:
    • CME: 1.00
    • ANCC/AANP: 1.00
  • Cost: Free
  • Release: Mar 29, 2017
  • Expires: Mar 28, 2018
  • Estimated Time to Complete:
    1 Hour(s)
  • Average User Rating:
    ( Ratings)




Needs Statement

Inflammatory bowel disease (IBD) affects a substantial number of individuals and though significant advances have been made in its treatment, many patients still do not achieve remission. As research reveals more insight into the pathophysiology of IBD, novel therapeutic targets are being identified that lead to the development of new therapeutic agents. These unique treatment options will give patients who have not been able to achieve treatment goals more options and a greater chance for success. As more information becomes available about IBD, gastroenterologists and other clinicians must be knowledgeable and fully prepared to use this information in their practice and employ new agents as they become available. Utilizing a panel of expert faculty and featuring video vignettes of actual patients, the objective of this web-based activity is to provide clinicians with a better understanding of the latest data regarding evolving treatment goals in IBD and about the adoption of an individualized treatment approach to the selection, initiation, and tailoring of biologic therapies for achieving and sustaining remission of IBD.


Target Audience

This activity is intended for gastroenterologists, nurse practitioners, nurses and physician assistants who work with gastroenterology practices and/or treat patients with IBD.



At the conclusion of this activity, participants will be able to (or better able to):

  • Assess patients who are unable to achieve remission to determine potential causes of treatment failure and modify treatment in an appropriate manner
  • Analyze the underlying mechanisms and disease progression of IBD and how it relates to current treatment strategies and the need for novel therapies
  • Discuss the safety and efficacy data for new and emerging therapeutic options for IBD, including unique mechanisms of action and potential place in therapy



Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Boston University School of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

1.00 CNE Contact Hour, all of which is eligible for pharmacology credit.


Faculty Disclosure

Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve apparent conflicts of interest. In addition, faculty members are asked to disclose when any discussion of unapproved use of pharmaceuticals and devices occurs.


Commercial Supporter

This educational activity is supported by an independent medical educational grant from Pfizer Inc.